Skip to main content

Improving Early Detection in Melanoma

Dr. Allan Halpern

Allan C. Halpern, MD, is an MSK internist and dermatologist whose work focuses on detecting and managing melanoma. He has pioneered the use of whole-body photography to improve early detection of the disease.

Dr. Peter Shore was the kind of physician that patients trusted implicitly for an accurate diagnosis, and they often sought his opinion even after he retired.

When Dr. Shore fell at age 87 and was taken to the emergency room, his two sons Graham and Howard found him completely alert to a physician’s questions. But two days later, Dr. Shore could barely speak. The diagnosis: a brain tumor.

Through genetic testing that can analyze tumor DNA, the Shores learned that the brain malignancy was a secondary cancer. The primary disease was melanoma, the most serious of skin cancers. It had metastasized to Dr. Shore’s brain and lungs.

Ironically, years earlier it was Dr. Shore who had noticed an unusual mole on Graham’s skin. His astute observation led to a diagnosis of early-stage melanoma and immediate treatment for his son.

In Dr. Shore’s case, there had been no prior sign that he was ill. The specialists did all they could, but the disease had progressed undetected for too long. Dr. Shore died a few months later.

The Importance of Early Detection

Dr. Shore had always impressed upon his family the importance of an early diagnosis. His sons, because of their family history, made regular appointments to have their skin checked for cancer. During a trip to New York City, Howard realized he was overdue for a skin check. The physician took a biopsy of a suspicious mole, which was diagnosed as stage I melanoma. Since it was discovered early, the cancer was easily removed. Howard, like Graham, was fortunate.

Howard had been referred to Memorial Sloan Kettering Cancer Center (MSK) where he met Allan Halpern, MD, Chief of the Dermatology Service. “I knew the moment I met him that I wanted to stay under his care, even though I don’t live in New York,” says Howard. “Dr. Halpern is a wonderful doctor, and MSK is an exceptional institution.”

Like our father, the doctors and all the personnel will always put the patient first.

–Howard Shore, MSK patient

MSK developed the very first drug to improve the lives of people with metastatic melanoma. It was approved by the FDA in 2011. But additional investment is essential to continue improving early detection of skin cancers, which is the core of Dr. Halpern’s work. The five-year survival rate of people with local stage I melanoma is 99%. For melanoma that has spread to distant organs, it is 27%.

An Innovative Approach

Dr. Halpern’s pioneering research makes use of whole-body photography to assist physicians in identifying cancerous moles when they are most treatable. He shared with the Shore brothers a program he is developing to apply artificial intelligence (AI) to skin imaging. It would enable anyone with a smartphone to proactively monitor their skin.

Howard and Graham were inspired by Dr. Halpern’s early adoption of technology and collaborative approach with researchers at medical centers across the globe. They generously decided to fund the program, known as the International Skin Imaging Collaboration (ISIC), through the Shore Family Fund.

The Impact of Giving

The brothers’ philanthropic partnership with MSK supports the development of an online database of skin images, which will foster the creation of AI algorithms needed to identify melanoma in its earliest forms.

“The holy grail,” says Graham, “is an AI-enhanced image that allows the physician to determine if a biopsy is necessary.” The siblings hope that their giving to the ISIC project will help accelerate the availability of this life-changing technology at cancer centers throughout the United States and other countries.

Philanthropy supports and accelerates innovations at MSK at a pace that was unthinkable just a decade ago. The Shore Family Fund will help drive transformational change in the early detection and diagnosis of melanoma.

–Dr. Allan Halpern

Howard and Graham are committed to remembering their father by supporting Dr. Halpern’s initiative. “At its core, MSK is an amazing institution with forward-thinking research and old-fashioned values,” says Howard. “Like our father, the doctors and all the personnel will always put the patient first.”

Join Graham and Howard’s Fight

You can join Graham and Howard by making a gift to help Memorial Sloan Kettering further early detection and treatments for all cancers. Contact the Office of Planned Giving at or 800-688-1827 to learn more about how you can make a difference.

A charitable bequest is one or two sentences in your will or living trust that leave to Memorial Sloan Kettering Cancer Center a specific item, an amount of money, a gift contingent upon certain events or a percentage of your estate.

An individual or organization designated to receive benefits or funds under a will or other contract, such as an insurance policy, trust, or retirement plan.

I bequeath to Memorial Sloan-Kettering Cancer Center, a New York nonprofit corporation having a principal place of business at 1275 York Avenue, New York, NY 10065, Federal Tax ID #13-1924236, ____percent of my total estate (or $_____, or other property) to be used or disposed of as Memorial Sloan-Kettering Cancer Center in its sole discretion deems appropriate.

able to be changed or cancelled

A revocable living trust is set up during your lifetime and can be revoked at any time before death. They allow assets held in the trust to pass directly to beneficiaries without probate court proceedings and can also reduce federal estate taxes.

cannot be changed or cancelled

tax on gifts generally paid by the person making the gift rather than the recipient

the original value of an asset, such as stock, before its appreciation or depreciation

the growth in value of an asset like stock or real estate since the original purchase

the price a willing buyer and willing seller can agree on

The person receiving the gift annuity payments.

the part of an estate left after debts, taxes and specific bequests have been paid

a written and properly witnessed legal change to a will

the person named in a will to manage the estate, collect the property, pay any debt, and distribute property according to the will

A donor-advised fund is an account that you set up but which is managed by a nonprofit organization. You contribute to the account, which grows tax-free. You can recommend how much (and how often) you want to distribute money from that fund to MSK or other charities. You cannot direct the gifts.

An endowed gift can create a new endowment or add to an existing endowment. The principal of the endowment is invested and a portion of the principal’s earnings are used each year to support our mission.

Tax on the growth in value of an asset—such as real estate or stock—since its original purchase.

Securities, real estate, or any other property having a fair market value greater than its original purchase price.

Real estate can be a personal residence, vacation home, timeshare property, farm, commercial property, or undeveloped land.

A charitable remainder trust provides you or other named individuals income each year for life or a period not exceeding 20 years from assets you give to the trust you create.

You give assets to a trust that pays our organization set payments for a number of years, which you choose. The longer the length of time, the better the potential tax savings to you. When the term is up, the remaining trust assets go to you, your family or other beneficiaries you select. This is an excellent way to transfer property to family members at a minimal cost.

You fund this type of trust with cash or appreciated assets—and may qualify for a federal income tax charitable deduction when you itemize. You can also make additional gifts; each one also qualifies for a tax deduction. The trust pays you, each year, a variable amount based on a fixed percentage of the fair market value of the trust assets. When the trust terminates, the remaining principal goes to MSK as a lump sum.

You fund this trust with cash or appreciated assets—and may qualify for a federal income tax charitable deduction when you itemize. Each year the trust pays you or another named individual the same dollar amount you choose at the start. When the trust terminates, the remaining principal goes to MSK as a lump sum.

A beneficiary designation clearly identifies how specific assets will be distributed after your death.

A charitable gift annuity involves a simple contract between you and MSK where you agree to make a gift to MSK and we, in return, agree to pay you (and someone else, if you choose) a fixed amount each year for the rest of your life.

A tax imposed at one's death on the transfer of most types of property. Currently federal estate taxes are assessed in 2022 on estates worth more than $11.2 million. The maximum estate tax rate is 40 percent. Some states also impose taxes at death that vary depending on state law.

A written legal instrument created by a grantor for the benefit of him/herself (during life) or others (during life or at death).

A revocable trust established by a grantor during his or her lifetime in which the grantor transfers some or all of his or her property into the trust.

Equity or debt instruments, typically shares listed on a stock exchange, which can be readily bought or sold.